Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Mild Cognitive Impairment AND Alzheimer Disease AND No treatment

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    72 result(s) found for: Mild Cognitive Impairment AND Alzheimer Disease AND No treatment. Displaying page 1 of 4.
    1  2  3  4  Next»
    EudraCT Number: 2015-005438-24 Sponsor Protocol Number: 1346.23 Start Date*: 2016-06-30
    Sponsor Name:Boehringer Ingelheim RCV GmbH & Co KG
    Full Title: A multi-centre, double-blind, parallel-group, randomised controlled study to investigate efficacy and safety of orally administered BI 425809 during a 12-week treatment period compared to placebo i...
    Medical condition: Cognitive impairment due to Alzheimer's Disease Patients with diagnosis of mild-to moderate Alzheimer's dementia according to the recommendations from the National Institute on Aging- Alzheimer'...
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10012271 Dementia Alzheimer's type PT
    20.0 10029205 - Nervous system disorders 10001896 Alzheimer's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) HU (Completed) NO (Completed) FI (Completed) GR (Completed) GB (Completed) ES (Completed) FR (Completed) IT (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2019-000604-15 Sponsor Protocol Number: PTC-19-602325 Start Date*: 2020-10-29
    Sponsor Name:UNIVERSITÀ DEGLI STUDI "G. D'ANNUNZIO" CHIETI-PESCARA
    Full Title: Multicentre, randomized, double-blind, placebo-controlled, parallel-group Phase II study aimed at evaluating the efficacy and safety of “Zinco Solfato” in Mild Cognitive Impairment due to Alzheimer...
    Medical condition: Prodromic Alzheimer's disease with evidence of cerebral amyloidosis.
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004852 10001896 Alzheimer's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2018-003567-66 Sponsor Protocol Number: T817MAEU201 Start Date*: 2019-06-11
    Sponsor Name:FUJIFILM Toyama Chemical Co., Ltd.
    Full Title: A Phase 2 multi-center, randomized, double-blind, placebo-controlled, parallel group study to evaluate the efficacy and safety of T 817MA in patients with mild cognitive impairment due to Alzheimer...
    Medical condition: Mild cognitive impairment due to Alzheimer's Disease or mild Alzheimer's Disease.
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004852 10001896 Alzheimer's disease LLT
    21.1 100000004852 10009846 Cognitive impairment LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) NL (Completed) GB (GB - no longer in EU/EEA) CZ (Completed) ES (Ongoing) HU (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2018-002102-31 Sponsor Protocol Number: 221AD205 Start Date*: 2019-03-20
    Sponsor Name:Biogen Idec Research Limited
    Full Title: A Phase 2, Multicenter, Randomized, Parallel-Group, Double-Blind, Controlled Study of Aducanumab (BIIB037) in Subjects With Mild Cognitive Impairment due to Alzheimer’s Disease or With Mild Alzheim...
    Medical condition: Mild Cognitive Impairment due to Alzheimer's Disease and Mild Alzheimer's Dementia
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004852 10001896 Alzheimer's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) FR (Completed) ES (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2014-002855-25 Sponsor Protocol Number: EIP-VX00-745-302 Start Date*: 2015-03-11
    Sponsor Name:EIP Pharma, LLC
    Full Title: A Clinical Study of Two Doses of a Selective p38 MAP Kinase Inhibitor, VX-745, to Evaluate the Effects of 12-Week Oral Twice-Daily Dosing on Amyloid Plaque Load as Assessed by Quantitative Dynamic ...
    Medical condition: Alzheimer’s disease
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004852 10001896 Alzheimer's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2020-005829-88 Sponsor Protocol Number: AH0003 Start Date*: 2021-09-28
    Sponsor Name:UCB Biopharma SRL
    Full Title: A Patient- and Investigator-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Bepranemab (UCB0107) in Study Participants With Prodromal to Mild Alzheimer’s Disea...
    Medical condition: Alzheimer’s Disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004852 10001896 Alzheimer's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) DE (Trial now transitioned) BE (Trial now transitioned) NL (Trial now transitioned) ES (Ongoing) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2011-005217-37 Sponsor Protocol Number: I4O-MC-BACC(b) Start Date*: 2012-08-22
    Sponsor Name:Eli Lilly and Company
    Full Title: Assessment of Safety, Tolerability, and Pharmacodynamic Effects of LY2886721 in Patients with Mild Cognitive Impairment Due to Alzheimer’s Disease or Mild Alzheimer's Disease
    Medical condition: Mild Cognitive Impairment Due to Alzheimer’s Disease or Mild Alzheimer's Disease
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004852 10001896 Alzheimer's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Prematurely Ended) ES (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2010-022596-64 Sponsor Protocol Number: DRI10734 Start Date*: 2011-01-27
    Sponsor Name:sanofi-aventis recherche & développement
    Full Title: Estudio internacional, multicéntrico, aleatorizado, doble ciego, con grupos paralelos y controlado con placebo del efecto sobre la función cognitiva, la seguridad y la tolerabilidad de SAR110894D, ...
    Medical condition: Demencia tipo enfermedad de Alzheimer_______________ Dementia Alzheimer's type
    Disease: Version SOC Term Classification Code Term Level
    12.1 10012271 Dementia Alzheimer's type LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) IT (Completed) PT (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2017-002901-37 Sponsor Protocol Number: 251AD201 Start Date*: 2018-06-04
    Sponsor Name:Biogen Idec Research Limited
    Full Title: Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Safety, Tolerability, and Efficacy of BIIB092 in Subjects with Mild Cognitive Impairment due to Alzheimer’s Disease ...
    Medical condition: Mild cognitive impairment (MCI) due to Alzheimer’s disease (AD) or mild AD
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004852 10001896 Alzheimer's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) SE (Completed) ES (Prematurely Ended) IT (Completed) PL (Completed) FR (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2020-003966-38 Sponsor Protocol Number: CADPT06A12201 Start Date*: 2021-06-30
    Sponsor Name:Novartis Pharma AG
    Full Title: EXploratory PLatform trial on Anti-INflammatory agents in Alzheimer’s Disease (EXPLAIN-AD): A randomized, placebo controlled, multicenter platform study to evaluate the efficacy, safety, tolerabili...
    Medical condition: Mild cognitive impairment due to Alzheimer’s disease and mild Alzheimer’s disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004852 10001896 Alzheimer's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Prematurely Ended) IS (Completed)
    Trial results: View results
    EudraCT Number: 2007-001846-42 Sponsor Protocol Number: CAQW051A2104 Start Date*: 2007-10-05
    Sponsor Name:Novartis Pharma AG
    Full Title: A 4-week, parallel-group, randomized, double-blind, placebo-controlled, adaptive proof of concept study of AQW051 at up to three dose levels for the treatment of patients with findings consistent w...
    Medical condition: Mild Alzheimer’s disease (AD) and amnestic mild cognitive impairment (amnestic MCI)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10001896 Alzheimer's disease LLT
    9.1 10009846 Cognitive impairment LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2019-003532-23 Sponsor Protocol Number: PBD01180 Start Date*: 2020-06-26
    Sponsor Name:Vivoryon Therapeutics N.V.
    Full Title: A Phase 2b Multicentre, Randomized, Double-blind, Placebo-controlled, Parallel Group Dose Finding, Safety, Tolerability and Efficacy Study of PQ912 in Subjects with Mild Cognitive Impairment and Mi...
    Medical condition: Mild Cognitive Impairment and Mild Dementia due to Alzheimer’s Disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10001896 Alzheimer's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed) DE (Completed) NL (Completed) ES (Ongoing) PL (Completed)
    Trial results: View results
    EudraCT Number: 2022-003384-24 Sponsor Protocol Number: NN6535-7519 Start Date*: 2023-03-08
    Sponsor Name:Novo Nordisk A/S
    Full Title: A randomised double-blind placebo-controlled clinical study investigating the effects of semaglutide s.c. once-weekly versus placebo on central and peripheral inflammation in participants with Alzh...
    Medical condition: Mild cognitive impairment (MCI) or mild dementia, both of the Alzheimer’s type
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004852 10001896 Alzheimer's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Trial now transitioned) DK (Trial now transitioned) IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2021-004809-40 Sponsor Protocol Number: GV1001-AD-CL2-007 Start Date*: 2022-10-10
    Sponsor Name:GemVax &KAEL Co., Ltd.
    Full Title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Design, Prospective, 52-Week, Phase 2 Clinical Study to Evaluate the Safety and Efficacy of GV1001 Administered Subcutaneously ...
    Medical condition: Mild to Moderate (stage 4 and 5) Alzheimer's Disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004852 10001896 Alzheimer's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Temporarily Halted) FR (Trial now transitioned) PT (Trial now transitioned) IT (Trial now transitioned) FI (Trial now transitioned) NL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2016-004352-30 Sponsor Protocol Number: AB1601 Start Date*: 2017-05-22
    Sponsor Name:Araclon Biotech, S.L.
    Full Title: A Multicenter, Randomized, Double-blind, Placebo-controlled, 24 months Study in Patients with amnestic Mild Cognitive Impairment or Very Mild Alzheimer’s Disease to Investigate the Safety, Tolerabi...
    Medical condition: Alzheimer's disease
    Disease: Version SOC Term Classification Code Term Level
    19.1 100000004852 10001896 Alzheimer's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) SE (Completed) FR (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2015-002147-34 Sponsor Protocol Number: AZT-001 Start Date*: 2016-01-21
    Sponsor Name:AZTherapies, Inc.
    Full Title: A phase III Safety and Efficacy Study of ALZT-OP1 in Subjects with Evidence of Early Alzheimer’s Disease.
    Medical condition: Early stage of Alzheimer's Disease.
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004852 10001896 Alzheimer's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) CZ (Completed) BG (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2015-002145-63 Sponsor Protocol Number: INMiND-02 Start Date*: 2015-10-15
    Sponsor Name:University of Southampton
    Full Title: A double-blind, placebo-controlled study of the effect of a TNF alpha inhibitor, etanercept (Enbrel), on microglial activation in amyloid PET positive patients with Mild Cognitive Impairment due to...
    Medical condition: Mild Cognitive impairment- due to Alzheimer's disease- intermediate likelihood
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004852 10001896 Alzheimer's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2019-003302-27 Sponsor Protocol Number: ANAVEX2-73-AD-004 Start Date*: 2020-01-22
    Sponsor Name:Anavex Germany GmbH
    Full Title: A Phase 2b/3, Double-Blind, Randomised, Placebo-Controlled 48 week Safety and Efficacy trial of ANAVEX2-73 for the Treatment of Early Alzheimer’s Disease (AD).
    Medical condition: Alzheimer's Disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004852 10001896 Alzheimer's disease LLT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) NL (Completed) DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-005292-17 Sponsor Protocol Number: TRx-237-008 Start Date*: 2012-10-02
    Sponsor Name:TauRx Therapeutics Ltd
    Full Title: A Double-Blind, Placebo-Controlled, Randomised, 4-Week Safety and Tolerability Study of LMTM in Subjects with Mild to Moderate Alzheimer’s Disease on Pre-Existing Stable Acetylcholinesterase Inhibi...
    Medical condition: Alzheimer’s Disease
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004852 10001896 Alzheimer's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2014-002601-38 Sponsor Protocol Number: D5010C00009 Start Date*: 2015-01-29
    Sponsor Name:Eli Lilly and Company
    Full Title: A 24-Month, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy, Safety, Tolerability, Biomarker and Pharmacokinetics Study of AZD3293 in Early Alzheimer’s Disease (...
    Medical condition: Early Alzheimer’s Disease (mild cognitive impairment due to AD (ie, prodromal AD) and mild dementia of the Alzheimer’s type)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10012271 Dementia Alzheimer's type PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) BE (Prematurely Ended) DE (Completed) ES (Completed) HU (Completed) FR (Completed) IT (Prematurely Ended)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu May 01 06:08:18 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA